ClinicalTrials.gg
CompletedNCT02966301GvHD-ATOUpdated May 9, 2022Results posted

Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

A Phase 2 interventional study of Arsenic Trioxide Injectable Solution in Chronic Graft-Versus-Host Disease and Immune System Diseases, sponsored by Medsenic. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.

Sponsored by Medsenic · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the early chronic GvHD events (first line therapy), if the addition of arsenic trioxide to standard therapy with corticosteroids, with or without cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of corticosteroid therapy

Read the detailed description

Graft-versus-host disease (GvHD) is the most common long-term complication in patients who underwent allogeneic transplantation.

First-line therapy for chronic GVHD is based on immunosuppressive agents (corticosteroids with or without cyclosporine) achieving satisfactory response in around 30% of patients.

This is a prospective, national, multicenter, non-randomized Phase II study that will include a total number of 24 patients in which, trioxide d'arsenic will be administrated at 0,15mg/kg/day.

Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus.

Follow-up visits will be weekly for four weeks (ATO cycle), every two weeks from second to third month of ATO treatment, every month from the fourth to sixth month of ATO treatment and every 3 months, at 9 months and 12 months (final visit).

02

Conditions studied

  • Chronic Graft-Versus-Host Disease
  • Immune System Diseases

Keywords

  • cGvHD
  • Arsenic Trioxide
  • Hematology
03

In context

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

This study's enrollment of 21 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.

Browse Bronchiolitis Obliterans Syndrome studies →

Lead sponsor

This is the only study on the registry with Medsenic as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years) who have received a first stem cell transplantation for a hematological disease (any source of hematopoietic stem cells is authorized; any category of conditioning regimen prior to allo-SCT is authorized; any type of stem cell donors is authorized)
  • Confirmed diagnosis of a first episode of chronic GvHD requiring systemic therapy (any prior GvHD prophylaxis previously used is accepted). Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus. Chronic GvHD diagnosis will be based on the evaluation of the severity of the different clinical manifestations including:

    • Performance status evaluation
    • Cutaneous evaluation measured by the percentage of extension or the presence of sclerotic features. If relevant, confirmation with a should be performed whenever possible
    • Oral symptoms
    • Ocular symptoms
    • Gastro-intestinal symptoms
    • Evaluation of liver involvement (total , transaminases and alkaline phosphatases)
    • Pulmonary function evaluation
    • Evaluation of the musculoskeletal manifestations, especially the amplitude of the relevant articulations
    • Genital tract symptoms
  • Signed
  • Absence of to the use of ATO
  • Subjects affiliated with an appropriate social security system
  • Men must use a medically acceptable method of throughout the treatment period and for at least 4 months and 10 days following the last treatment administration
  • Women who are of must have a negative serum pregnancy test and agree to use a medically acceptable method of contraception throughout the study and for 3 months following the end of the study
  • Patient not participating or not having participated in a clinical study in the 30 days prior to his/her inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • Patient developing acute GvHD (whether early or "late onset" form)
  • Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus (presence of one or more acute GvHD manifestations in a patient with a diagnosis of chronic GvHD)
  • A "mild" form of chronic GvHD not requiring systemic therapy
  • A "moderate" form of chronic GvHD limited to one organ site not requiring systemic immunosuppressive therapy
  • Patient receiving mycophenolate mofetil
  • Not the first episode of chronic GvHD needing systemic immunosuppressive therapy
  • Second stem cell transplant
  • Severe cardiac diseases (congestive heart failure ( class III), recent myocardial infarction (in the past 6 months before the inclusion), histories of unexplained syncope, ...)
  • Significant arrhythmias, (EKG) abnormalities:
  • Congenital syndromes
  • History or presence of significant ventricular or atrial tachyarrhythmia
  • resting bradycardia (\< 50 beats per minutes)
  • QTc>450msecformenand>470msecfor women on screening EKG (using the QTcF formula)
  • Right bundle branch block plus left anterior hemiblock, bifascicular block
  • Central or peripheral neuropathy
  • Neutrophils \< 0.5 × 109/L
  • \< 50 × 109/L
  • Potassium ≤ 4 mEq/l*
  • Magnesium ≤ 1.8 mg/dl*
  • Calcium ≤ 2.15 mmol/l*
  • Hepatic impairment due to a suspected or proven liver damage, other than direct hepatic cGvHD involvement
  • PT \< 50%
  • Renal impairment (creatinine ≥ 100 μmol/l)
  • Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patients' death within 1 month after the start of therapy
  • Severe neurological or psychiatric disorders
  • Denied
  • Pregnancy
  • Women breastfeeding at selection and throughout the treatment period

    • If abnormal at selection, to be corrected and re-validated following electrolytes infusion, before inclusion and each drug perfusion.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    interventional

    Single arm : Arsenic trioxide

    Drug: Arsenic Trioxide Injectable Solution

Interventions

  • Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle). Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy. The study duration will be 2 years (12 months recruitment + 12 months follow-up).

    Also known as: Trisenox / Arscimed

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide

    Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus. Response definition is as follows: * Complete remission (CR) is defined as complete disappearance of any sign of chronic GvHD. * Partial remission (PR) is defined as a significant improvement as defined by the organ or site specific measurement scale without progression in any other organ or site.

    Time frame: six months

Secondary outcomes

  1. Average Dose of Corticosteroids

    Average dose in mg/kg/day of prednisone or prednisone equivalent

    Time frame: Average dose of Prednisone at 6 months after the first infusion of ATO

  2. Failure Free Survival

    Treatment failure were defined by: * Initiation of a new systemic treatment for chronic GvHD; * Recurrent or progressive malignancy; * Death

    Time frame: 6 months after first ATO infusion

  3. Number of Adverse Events

    Tolerability and safety of ATO in combination with Prednisone, with or without Ciclosporine, in patients with chronic GvHD after allo-SCT. Adverse events follow-up for all patients throughout the study

    Time frame: 12 months after the first infusion of ATO for each patient

  4. Cumulative Incidence for Non-relapse Mortality (NRM)

    Non-Relapse Mortality (NRM) of infectious and non-infectious origin

    Time frame: 12 months after first ATO infusion

07

Results

Posted May 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneArsenic Trioxide Injectable Solution
Started21
Full analysis set (fas)20
Safety analysis (sa)21
Completed18
Not completed3
Withdrew: Death2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide

Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus. Response definition is as follows: * Complete remission (CR) is defined as complete disappearance of any sign of chronic GvHD. * Partial remission (PR) is defined as a significant improvement as defined by the organ or site specific measurement scale without progression in any other organ or site.

Time frame:
six months
Reported as:
Count of participants · Participants
Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide
ParticipantsInterventional
Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide15
SecondaryAverage Dose of Corticosteroids

Average dose in mg/kg/day of prednisone or prednisone equivalent

Time frame:
Average dose of Prednisone at 6 months after the first infusion of ATO
Reported as:
Mean · mg/kg/day
Average Dose of Corticosteroids
mg/kg/dayInterventional
Average Dose of Corticosteroids0.22 ± 0.29
SecondaryFailure Free Survival

Treatment failure were defined by: * Initiation of a new systemic treatment for chronic GvHD; * Recurrent or progressive malignancy; * Death

Time frame:
6 months after first ATO infusion
Reported as:
Number · percentage of participants
Failure Free Survival
percentage of participantsInterventional
Failure Free Survival90 (65.6 to 97.4)
SecondaryNumber of Adverse Events

Tolerability and safety of ATO in combination with Prednisone, with or without Ciclosporine, in patients with chronic GvHD after allo-SCT. Adverse events follow-up for all patients throughout the study

Time frame:
12 months after the first infusion of ATO for each patient
Reported as:
Number · number of events
Number of Adverse Events
number of eventsInterventional
Number of Adverse Events197
SecondaryCumulative Incidence for Non-relapse Mortality (NRM)

Non-Relapse Mortality (NRM) of infectious and non-infectious origin

Time frame:
12 months after first ATO infusion
Reported as:
Number · percentage of participants
Cumulative Incidence for Non-relapse Mortality (NRM)
percentage of participantsInterventional
Cumulative Incidence for Non-relapse Mortality (NRM)5 (0.3 to 21.1)

Adverse events

Collected over For each patient the specific period over which data on adverse events were collected is 1 year after inclusion in the clinical study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arsenic Trioxide Infusion2/21 (9.5%)21/21 (100%)21/21 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventArsenic Trioxide Infusion
Urinary tract infectionInfections and infestations3/21
Lung disorderRespiratory, thoracic and mediastinal disorders2/21
HepatotoxicityHepatobiliary disorders2/21
PneumonitisRespiratory, thoracic and mediastinal disorders1/21
Respiratory distressRespiratory, thoracic and mediastinal disorders1/21
Respiratory tract infection viralRespiratory, thoracic and mediastinal disorders1/21
PancytopeniaBlood and lymphatic system disorders1/21
EncephalopathyNervous system disorders1/21
EpilepsyNervous system disorders1/21
Oedema peripheralGeneral disorders1/21
Most frequent other events
Showing 10 of 103
Most frequent other events
EventArsenic Trioxide Infusion
CoughRespiratory, thoracic and mediastinal disorders9/21
DiarrhoeaGastrointestinal disorders8/21
Oedema peripheralGeneral disorders7/21
PyrexiaGeneral disorders5/21
HypokalaemiaMetabolism and nutrition disorders4/21
AstheniaGeneral disorders3/21
DyspnoeaRespiratory, thoracic and mediastinal disorders3/21
Abdominal painGastrointestinal disorders3/21
ErythemaSkin and subcutaneous tissue disorders3/21
HypogammaglobulinaemiaImmune system disorders2/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arsenic Trioxide
Mean62 (42 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Arsenic Trioxide
Female11
Male10
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arsenic Trioxide
Region of Enrollment
Region of Enrollment(participants)Arsenic Trioxide
France21
Diagnosis of chronic GvHD requiring systemic immunosuppressive therapy confirmed,
Diagnosis of chronic GvHD requiring systemic immunosuppressive therapy confirmed,(Participants)Arsenic Trioxide
Count of participants21
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Rongvaux-Gaida D, Dupuis M, Poupon J, Djebrani-Oussedik N, Lemonnier C, Rieger F. High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 Oct;28(10):679.e1-679.e11. doi: 10.1016/j.jtct.2022.07.004. Epub 2022 Jul 10. PubMed 35830931 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jun 2020, 42 months.

Results were first posted in May 2022, 1 year 11 months after primary completion.

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 17, 2016
StartActual
Dec 2016
Primary completionActual
Jun 2020
CompletionActual
Jun 2020
Results first posted
May 9, 2022
Last update
May 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02966301
Lead sponsor
Medsenic
Responsible party
Sponsor
First posted
Nov 17, 2016
Start date
Dec 2016
Primary completion
Jun 2020
Completion
Jun 2020
Results posted
May 9, 2022
Last update
May 9, 2022

Study contacts

Mohamad Mohty, Pr
principal investigator · Hôpital Saint-Antoine, AP-HP - Paris
Anne Huyhn, Dr
principal investigator · Institut Universitaire du Cancer - Oncopole - Toulouse
Sylvain Chantepie, Dr
principal investigator · Institut d'Hématologie de Basse Normandie - CHU de Caen
Patrice Chevallier, Dr
principal investigator · Hôtel Dieu - CHU Nantes
Didier Blaise, Pr
principal investigator · Institut Paoli Calmettes - Centre de Recherche en Cancérologie de Marseille
Patrice Ceballos, Dr
principal investigator · Hôpital St Eloi - Montpellier
Patrice Turlure, Dr
principal investigator · University Hospital, Limoges
Edouard Forcade, Dr
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arsenic Trioxide

Start the discussion